4//SEC Filing
Cohen Yuval 4
Accession 0000950170-25-022512
CIK 0001595097other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 5:40 PM ET
Size
5.9 KB
Accession
0000950170-25-022512
Insider Transaction Report
Form 4
Cohen Yuval
DirectorChief Executive Officer
Transactions
- Sale
Common Stock, par value $0.0001 per share
2025-02-14$8.76/sh−7,134$62,465→ 138,187 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.
Documents
Issuer
Corbus Pharmaceuticals Holdings, Inc.
CIK 0001595097
Entity typeother
Related Parties
1- filerCIK 0001626003
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 5:40 PM ET
- Size
- 5.9 KB